We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Reversible Secondary Myelofibrosis or Clonal Myeloproliferative Disorder

This study has been terminated.
(This study was stopped due to poor enrollment numbers)
Sponsor:
ClinicalTrials.gov Identifier:
NCT00722254
First Posted: July 25, 2008
Last Update Posted: March 21, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
University of Utah
  Purpose
To determine the prevalence of myelofibrosis in patients with primary pulmonary hypertension, and to discover if the fibrosis in these patients is primary (AMM) or secondary.

Condition
Primary Myelofibrosis Primary Pulmonary Hypertension Secondary Myelofibrosis Pulmonary Arterial Hypertension

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Reversible Secondary Myelofibrosis or Clonal Myeloproliferative Disorder

Resource links provided by NLM:


Further study details as provided by University of Utah:

Primary Outcome Measures:
  • Determine the prevalence of myelofibrosis in patients with primary pulmonary hypertension [ Time Frame: After sample is obtained ]

Secondary Outcome Measures:
  • Discover if the fibrosis in patients with primary pulmonary hypertension is primary (AMM) or secondary. [ Time Frame: After sample is obtained ]
  • Clonality [ Time Frame: After sample is obtained ]

Biospecimen Retention:   Samples With DNA
Whole Blood

Enrollment: 15
Study Start Date: June 2006
Study Completion Date: February 2009
Primary Completion Date: February 2009 (Final data collection date for primary outcome measure)
Groups/Cohorts
PPH
Subjects diagnosed with primary pulmonary hypertension (PPH)
Myelofibrosis
Subjects diagnosed with Primary or Secondary Myelofibrosis

  Show Detailed Description

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients suffering from primary pulmonary hypertension or myelofibrosis (primary or secondary)
Criteria

Inclusion Criteria:

  1. > 18 years of age
  2. Signed Informed Consent
  3. Subjects diagnosed with Primary Pulmonary Hypertension or Myelofibrosis (primary or secondary)

Exclusion Criteria:

  1. Anyone not meeting the above inclusion criteria
  2. Pregnant women
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00722254


Locations
United States, Utah
University of Utah
Salt Lake City, Utah, United States, 84132
VA Salt Lake City Health Care System
Salt lake City, Utah, United States, 84148
Sponsors and Collaborators
University of Utah
National Cancer Institute (NCI)
Investigators
Principal Investigator: Josef T Prchal, MD University of Utah
  More Information

Publications:

Responsible Party: University of Utah
ClinicalTrials.gov Identifier: NCT00722254     History of Changes
Other Study ID Numbers: 17806
1P01CA108671-01A2 ( U.S. NIH Grant/Contract )
First Submitted: July 23, 2008
First Posted: July 25, 2008
Last Update Posted: March 21, 2016
Last Verified: March 2016

Keywords provided by University of Utah:
Myeloproliferative Disorder
Primary Myelofibrosis
Primary Pulmonary Hypertension
Secondary Myelofibrosis
Pulmonary Arterial Hypertension
Flolan
Clonality
CD34+ cells
Hematologic abnormalities

Additional relevant MeSH terms:
Familial Primary Pulmonary Hypertension
Hypertension
Neoplasm Metastasis
Hypertension, Pulmonary
Primary Myelofibrosis
Myeloproliferative Disorders
Vascular Diseases
Cardiovascular Diseases
Neoplastic Processes
Neoplasms
Pathologic Processes
Lung Diseases
Respiratory Tract Diseases
Bone Marrow Diseases
Hematologic Diseases